Anorexia, malaise, abdominal discomfort or pain, dysphagia, nausea, vomiting, and diarrhea have occurred. These are more frequent with large doses or after one to three months of continuous therapy. A few patients have had sudden onset of profuse, watery diarrhea. Discontinue EDECRIN (ethacrynic acid) if diarrhea is severe and do not give it again. Gastrointestinal bleeding has occurred in some patients. Rarely, acute pancreatitis has been reported.
Reversible hyperuricemia and acute gout have been reported. Acute symptomatic hypoglycemia with convulsions occurred in two uremic patients who received doses above those recommended. Hyperglycemia has been reported. Rarely, jaundice and abnormal liver function tests have been reported in seriously ill patients receiving multiple drug therapy, including EDECRIN (ethacrynic acid) .
Agranulocytosis or severe neutropenia has been reported in a few critically ill patients also receiving agents known to produce this effect. Thrombocytopenia has been reported rarely.
Henoch-Schönlein purpura has been reported rarely in patients with rheumatic heart disease receiving multiple drug therapy, including EDECRIN (ethacrynic acid) .
Special Senses (see WARNINGS)
Deafness, tinnitus and vertigo with a sense of fullness in the ears, and blurred vision have occurred.
Central Nervous System
Headache, fatigue, apprehension, confusion.
Skin rash, fever, chills, hematuria.
SODIUM EDECRIN (ethacrynic acid) occasionally has caused local irritation and pain after intravenous use.